Buse et al. [33] summarized the recommendations from the 2019 update from the ADA and the European Association for the Study of Diabetes, especially concerning Glucagon-like peptide 1 (GLP-1) receptor and sodium-glucose cotransporter 2 (SGLT2) medications. The gene discussed is SLC5A2; the disease is diabetes mellitus.